Iovance Biotherapeutics (IOVA) revenue breakdown
By product, Amtagvi is the largest at 83% of fiscal 2025 revenue, growing 112% a year over 1 years.
By region, Federal income tax is the largest at 98% of fiscal 2025 revenue, growing 61% a year over 1 years.
Revenue by product
Fiscal years, as Iovance Biotherapeutics reports them in its 10-K filings; fiscal 2025 total $264M.
| Products | 2024 | 2025 | Share |
|---|---|---|---|
| Amtagvi | $104M | $220M | 83% |
| PROLEUKIN | $61M | $43M | 17% |
Revenue by region
Fiscal years, as Iovance Biotherapeutics reports them in its 10-K filings; fiscal 2025 total $264M.
| Regions | 2024 | 2025 | Share |
|---|---|---|---|
| Federal income tax | $161M | $259M | 98% |
| Non-US | $3M | $4M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IOVA.
Open IOVA in InvestinglyQuestions
Where does Iovance Biotherapeutics make its money?
In fiscal 2025, by product: Amtagvi $220M, PROLEUKIN $43M.
From Iovance Biotherapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.